** Shares of diabetes device makers fall between 1% to 3% before the bell
** Eli Lilly LLY.N says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial
** Shares of Dexcom DXCM.O, which manufactures continuous glucose monitors, down 2.6% at $66.94 premarket
** Shares of insulin pump makers Tandem Diabetes Care TNDM.O and Insulet Corp PODD.O down around 2% each
** LLY shares rise 13.4% to $833.56 premarket
** As of last close, DXCM down 11.6%, TNDM down 52.1%, LLY down 4.8%, PODD down 4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。